ReviewWiener klinische Wochenschrift2026
Systematic evidence analysis of symptom modification in hip osteoarthritis following MSC-based interventions.
Review in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting late failure in cartilage repair: the need for structural and biochemical monitoring in long-term ACI follow-up.Wiener klinische Wochenschrift · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal stromal/stem cell (MSC)-based interventions are increasingly used for hip osteoarthritis (HOA), although the products and supporting clinical evidence are heterogeneous. This systematic review evaluated symptom modification, safety, and methodological quality.
methodsPubMed/MEDLINE was searched on 1 August 2024 using MeSH and free-text terms. One author performed study screening, data extraction, and risk of bias assessment using the Downs and Black checklist and 9 studies comprising 307 patients were included. Because of clinical and methodological heterogeneity, results were synthesized descriptively; weighted outcome means were calculated only from studies reporting compatible baseline and follow-up values.
resultsThe interventions included culture-expanded MSCs, bone marrow concentrate, stromal vascular fraction, and micro-fragmented adipose tissue, with or without platelet-rich plasma. In contributing cohorts, VAS pain scores decreased from 6.7 to 3.7 (n = 58), WOMAC scores decreased from 35.4 to 18.5 (n = 49), and Harris hip scores increased from 40.8 to 62.8 (n = 76). These findings represent within-group changes rather than comparative treatment effects. Serious adverse events were uncommon, but reporting was incomplete and follow-up was generally limited.
conclusionThe use of MSC-based interventions was associated with encouraging short-term within-group improvements in pain and function; however, small samples, product heterogeneity, predominantly uncontrolled designs and limited safety reporting preclude conclusions regarding efficacy or structural disease modification. Adequately powered randomized controlled trials with standardized products and outcomes are required.
Indexed as
Identifiers
42803956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.